A study of LBL-024 combination for advanced solid tumors
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug combination (LBL-024) for people with advanced solid tumors, including bile duct and liver cancers. It aims to see if the treatment is safe and effective for those who have not responded to other therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- Your overall health should be fairly good (able to do daily activities without help).
- Your doctor expects you to live at least 3 more months.
- You must have at least one tumor that can be measured on scans.
- Your blood counts and organ function must be within acceptable ranges.
- If you are able to have children, you must agree to use effective birth control during the study and for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination for people with advanced non-small cell lung cancer or other solid tumors. It aims to see if adding LBL-024 to other treatments can help shrink tumors or slow their growth.
This trial tests a new drug combination for advanced solid tumors, specifically esophageal cancer. It may help people whose cancer has not responded to other treatments.
This trial tests a new combination drug called LBL-024 in people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see if the treatment can help shrink the tumor or slow the cancer's growth.
This trial tests LBL-024 in people with advanced cancer to see how it works and how safe it is. You may consider it if you are well enough for study visits and have time to complete at least about 12 weeks of follow-up.
This trial tests a new drug called BL-B01D1, alone or together with other drugs, in people with advanced liver cancer that has not improved with other treatments. The goal is to see if these combinations can help shrink tumors or slow the cancer's growth.
This trial tests a combination of three medicines—an immunotherapy (sintilimab), an anti-angiogenic drug (bevacizumab), and two chemotherapy drugs (gemcitabine and cisplatin, called AG)—as a first treatment for bile duct cancer that cannot be removed by surgery. The goal is to see if this cocktail can shrink tumors or slow their growth better than standard therapy.
Hear when a new Advanced Solid Tumour trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.